Rockwell Medical Inc. is an American company that develops and commercializes treatments against diseases such as renal and chronic kidney disease.

According to the law firm press release, the lawsuit alleges that throughout the Class Period, Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) the primary product offering for Triferic will be in a powder packet packaging, which the FDA has not yet approved; (2) Rockwell Medical is seeking to obtain transitional add-on payment reimbursement for Triferic with the Centers for Medicare & Medicaid Services instead of bundled reimbursement; and (3) as a result, Defendants’ statements about Rockwell Medical’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

On May 20, 2016, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiffs filed an amended complaint on July 26. A second amended complaint was filed on November 21.

Defendants filed a Motion to Dismiss the amended Complaint on January 6, 2017. On March 30, 2018, the Court issued an Order granting Defendants' Motion to Dismiss. The case was dismissed with prejudice.